前地区销售经理直接举报,辉瑞新药陷入商业贿赂丑闻

健识局
03 Feb

1月24日,美国司法部发布声明:辉瑞承诺支付5974.6万美元的和解费,折合人民币4.3亿元,以解决针对其全资子公司Biohaven带金销售的指控。Biohaven是辉瑞在2022年5月豪掷116亿美元收购的神经科学公司。这场收购的主要目标是全球首款可以预防和治疗偏头痛的药物瑞美吉泮。2020年,瑞美吉泮在美国上市。辉瑞在收购时的统计数据显示,在偏头痛领域,瑞美吉泮是美国处方量排名第一的CGRP...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10